URIHK

Ulinastatin is a serine protease inhibitor that reduces the pro-inflammatory responses as a result of sepsis, acute pancreatitis, trauma or surgery.

Ulinastatin was for the first time launched in Japan in 1985. In the year 1999 it was introduced in China and that is where the world realised the benefits that this molecule had to offer. By the year 2010 the monthly sales of this product reached 1 million vials/mth in China alone.

In the year 2012 this molecule was first introduced in India by Bharat Serums and almost for 3 years it had a free run with no competitor brand.

The year 2015 saw the introduction of two more brands in India but still the sales were not significant.

While in terms of population India and China were almost the same however the usage in India was nowhere close to the consumption in the Chinese market.

It was in 2019 that URIHK entered the Indian market and introduced their brand of Ulinastatin. With very smart positioning and strong scientific backing Ulinastatin market saw a revival of fortunes and the market started reflecting a healthy growth of almost 25%.

In addition to this in terms of units sold Urihk became the No.2 player in Indian market beating brands from strong and reputed multinational giants like Lupin & Abbott. Urihk’s brand of Ulinastatin has over 20% MS in terms of units in less than a year of introduction.

Ulinastatin for injection is available in two forms i.e liquid and lyophilised powder.

The approved Indian for usage in India is Sepsis & acute pancreatitis.